Research table: Sacituzumab govitecan (Trodelvy) for treatment of metastatic breast cancer

This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.

Introduction: Sacituzumab govitecan (Trodelvy) is a Trop-2 antibody-drug conjugate. It combines a Trop-2 antibody and the chemotherapy drug irinotecan. This combination allows the targeted delivery of irinotecan to cancer cells that express Trop-2.

Sacituzumab govitecan is used to treat metastatic triple negative breast cancers that have already been treated with at least 2 drug therapies in the metastatic setting. It helps shrink tumors and may improve survival.

Learn more about sacituzumab govitecan, including its side effects.

Study selection criteria: Randomized clinical trials with 100 or more participants with HER2-positive metastatic breast cancer.


Study Population
(number of participants)

Drug(s) Used

Objective Response Rate—Percent who Responded to Treatment
(95% CI)

Overall Survival
Better with
Sacituzumab Govitecan Compared to Chemotherapy

Randomized clinical trials

ASCENT trial [1]


Sacituzumab govitecan alone





Chemotherapy alone (eribulin, vinorelbine, capecitabine, or gemcitabine)



* 61 of the 529 participants had brain metastases.

† Compared to people who got chemotherapy, people who got sacituzumab govitecan were less likely to die (from breast cancer or other causes), with a hazard ratio of 0.51 (0.41-0.62). Among participants who did not have brain metastases, overall survival at 1 year was 46% among those who got sacituzumab govitecan and 19% among those who got chemotherapy.


  1. Bardia A, Hurvitz SA, Tolaney SM, et al. for the ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 384(16):1529-1541, 2021.

Updated 07/08/22